Podcasts about Neuropathology

We're back with Part Two of our special highlights podcasts from the International Lewy Body Dementia Conference in Amsterdam! This time, host Dr Sterre de Boer (Alzheimer's Centre Amsterdam) leads the discussion with a fantastic panel of experts:

Recent progress in neurogenetics and molecular pathology has improved our understanding of the complex pathogenetic changes associated with neurodegenerative dementias. In this episode, Katie Grouse, MD, FAAN, speaks with Sonja W. Scholz, MD, PhD, FAAN, an author of the article “Genetics and Neuropathology of Neurodegenerative Dementias,” in the Continuum® December 2024 Dementia issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Scholz is a senior investigator at the National Institutes of Health in Bethesda, Maryland and an adjunct professor of neurology at Johns Hopkins University in Baltimore, Maryland. Additional Resources Read the article: Genetics and Neuropathology of Neurodegenerative Dementias Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Full episode transcript available here:  Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Sonia Scholz about her article on genetics and neuropathy of neurodegenerative dementias, which appears in the December 2024 Continuum issue on dementia. Welcome to the podcast, and please introduce yourself to our audience.  Dr Scholz: Thank you so much for inviting me. My name is Sonia Scholz. I'm a neurologist working at the National Institutes of Health. My main focus of research and clinical work are neurodegenerative diseases, and I have a particular interest in using modern genomic tools to understand these diseases and potentially leverage it for new translational applications. Dr Grouse: Sonia, we're really excited to have you today and thanks for joining us.  Dr Scholz: I'm pleased to be here.  Dr Grouse: I'd like to start by asking what you think is the most important message or takeaway point from your article? Dr Scholz: So, this is an article that really captures a very broad and exciting field. So, one thing I wanted to really highlight is that there's a lot of heterogeneity, clinical, pathological, molecular heterogeneity in age-related neurodegenerative dementia syndromes. Our article was really aimed at providing a bird's eye view of the pertinent pathological characteristics, but also important genetic advances and insights and how we can leverage that, particularly in the new physician medicine era, hopefully come up with better treatments and better ways to counsel our patients.  Dr Grouse: What do you think is the most challenging aspect of understanding the genetics and neuropathologic basis of neurodegenerative dementias?  Dr. Scholz: That's a good question. There're many big and challenging questions, but I think one of the things we struggle the most with is really the heterogeneity. I see patients with one and the same Mendelian form of dementia. One patient is in their forties another patient is in their eighties, and the clinical manifestations can be very different from one patient to another. There's a lot of heterogeneity, also, on the pathological level. Not every patient has exactly the same distribution. And so, we're starting to slowly define what the underlying causes are, but it's still quite baffling and quite challenging to put them together and understand them. Dr Grouse: Do you feel that the genome-wide association studies has helped our understanding of these diseases, specifically the heterogeneity? And if so how?  Dr Scholz: That's a great question, but you're talking to a geneticist here. And I definitely would say genome-wide association studies have helped us a lot in identifying what the underlying disease pathways are and what the relationships between neurodegenerative disease entities are. It really also gave us a better understanding of apparently sporadic diseases where genetic factors are still playing a role. And we can leverage that type of knowledge increasingly to highlight high-risk groups, but also, we can increasingly use it to stratify patients for clinical trials, for example. And that's really exciting and there's still a lot of knowledge that we have to garner very quickly, especially in the non-Alzheimer dementia space.  Dr Grouse: You've mentioned, of course, the heterogeneity and these syndromes. And in your article, you go into a lot of the issue of the significant crossover between the genetic links and the neuropathological findings for the various types of neurodegenerative dementias. Do you think that this crossover has been more of a help or a hindrance in better understanding these diseases? Dr Scholz: Yeah, it can be a little bit, you know, challenging to wrap one 's mind around it. But by and large, I think it's actually good news because it highlights that there is a shared biology between many of the neurodegenerative disease entities. And by figuring out which the pathways are that are very often involved, we can prioritize certain targets for therapy development. But we can also be smarter about how we developed treatments. We could repurpose a drug that has been developed for Alzheimer's disease very easily for Lewy body dementia because we increasingly understand the overlap. And we can also leverage new clinical trials design, like basket trials. This is something that has been really transformative in the oncology sphere and now, increasingly, neurodegeneration. We're trying to apply that kind of thinking as well to our patient populations. Dr Grouse: What do you think our listeners will find to be most surprising when they read the article? Dr Scholz: We often present these diseases in our textbooks as these black-and-white entities, but the reality is that there's a lot of overlap. And we also see that co-pathologies are actually the norm and not the exception, and a lot of the molecular risk factors are shared. It's not really surprising. And I think that overlap and crosstalk between the various diseases is something that's a little bit strange to think about, but it actually makes increasingly sense now that we see the genetic risk profiles coming up. Dr Grouse: In reading your article, I was really struck by how many, or how much the prior studies have been lacking in inclusion of different ethno-racial backgrounds in the patients who've been studied. How can this be improved going forward?  Dr Scholz: Yeah, thank you. That's a really important and crucial question, and I think it really takes the collective effort of everybody in the healthcare research community to improve upon that. We need to talk to our patients about genetic testing, about brain donation programs, about referrals to clinical trials, and don't feel shy about reaching out to our colleagues and academic centers, even if you don't have the resources in a smaller institution. We also not only need to engage with the communities, we also need to build up a healthcare research community that has representatives from these various communities. So, it's really a collective effort that we build up and are proactive about building a more equitable healthcare system and research system that works for all of us and that really is going to provide us with the precision medicines that work for everybody. Dr Grouse: What do you think is the biggest debate or controversy related to the genetics and neuropathology of neurodegenerative dementias?  Dr Scholz: Yeah, there are loads of interesting debates, but I think in my field, in particular in the genetics is what to do with risk variance. What is it that I actually communicate to the patient? Obviously, I can learn a lot on the bench and I think I can use a lot of the genetic risk factors for molecular modeling, etc. But to which extent should I share that information? Because genetic information is something that we cannot alter and many of the risk factors are actually mild, that they may never result in disease. And so, communicating risk with patients is something that's very challenging and we used to just steer away from it. But now the discussion is starting to shift a little bit. You know, nowadays we are starting to offer, for example, testing for the APOE4 allele in individuals who are considering antiamyloid therapies. And this really, this is precision medicine in his earliest days because it allows us to stratify patients into those that are high-risk versus low-risk and those that need more frequent follow-up or may be advised not to pursue this treatment. And we're probably going to see more of those discussions and the ethics around it. And it's even harder in an aged population where you know, you may never manifest any of the symptoms despite carrying a lot of these risk deals. Dr Grouse: You mentioned, you know, that testing, APOE4 testing for certain populations when deciding to do the antiamyloid immunotherapies. Apart from that, which I think is a really good example of where genetic testing makes sense, what other scenarios do you think it makes sense at this point in time to recommend genetic testing for symptomatic patients who are concerned about neurodegenerative dementias? Dr Scholz: Yeah. So, I usually have a very frank discussion with patients in whom I suspect the genetic etiology. So those are individuals who have a strong family history, individuals from very early onset of the disease where genetic testing may allow us to establish a molecular diagnosis, individualize and refine our counseling, and potentially get them into targeted clinical trials that may be suitable for that. Those are always very nuanced discussions, but I usually start with those high-risk individuals. Increasingly patients are, even with the apparently sporadic forms, are asking me about it. And then I have a frank discussions about the pros and cons and offer it to the patients who really would like to pursue it.  Dr Grouse: That makes a lot of sense. What about in the case of patients who are asymptomatic but might have high risks because of, well, family members with certain types of neurodegenerative dementias? When would it make sense, if ever, to do genetic testing for them? Dr Scholz: Yeah, that's a that's a tough situation, to be honest. By and large, I would say I would like to understand what the motivation is to learn about the genetic status. If the motivation is something like family planning, future care planning, etc, then it may be a reasonable thing. But I also want to make it very clear upfront that knowing a genetic status, at least aside from APOE status, at least for now, doesn't actually change the clinical management. And I want to make sure patients understand if they are trying to lower their risk, knowing that genetic status is not going to lower their risk. There are other things, brain health habits, that are really important, that patients should double down on: avoiding vascular disease, avoiding traumatic brain injury, excessive alcohol use, etcetera. It's a discussion that really tries to understand the motivations behind the testing. But some patients are very frank and they want to have it. They may want to contribute to the research community, and so in those instances we may offer it, but I also really want to make them understand that knowing a genetic diagnosis may be acceptable to them, but family members who are related to them may not wish to know. And they can really cause a lot of psychological stress that extends beyond the individual. And then that's something to really consider before actually pursuing testing. Dr Grouse: I think that's a really good reminder, especially about how this can even affect people outside of the patient themselves. I think a lot of us don't even think about that. And certainly, our patients may not either. Taking it a step further, thinking about newly available biomarkers, imaging modalities, how should we incorporate the use of these for our patients when we're suspicious of things like Alzheimer's disease or dementia with the Lewy bodies? Dr Scholz: So by and large these biomarkers are used in in the research area, but we can, in a given patient where maybe the clinical presentation is somewhat atypical, we can use it to help with our diagnostic impression. It doesn't get rid of the clinical evaluation, but at least it gives us a little bit more certainty. Here are the you know, the molecular features, the abnormal amyloid tau deposits, for example, that we're there we're detecting supports diagnosis. May also sometimes help in patients where we suspect there could be even the co-pathology going on where we get a mixture of features, where we can counsel the patients and you know, detecting copathologies is something that is certainly challenging. We know that patients who have more pathologies on average are not doing as well as the ones who have relatively pure disease forms. But this is also an area of intense research and as long as it's used judiciously to help with the diagnostic compression, to reduce a diagnostic odyssey, I think there's a lot of potential there to improve the clinical evaluations nowadays. Dr Grouse: It is really exciting to see the options that are opening up as the years go by, which brings me to my next question. There is certainly, as we know, this new category of disease modifying therapies that are available in the form of the anti-amyloid immunotherapies. What else do you think's on the horizon for treatment and prevention, neurodegenerative dementias, going down the road five, ten, fifteen years down the line?  Dr Scholz: Yeah, I think we're entering the era of precision medicine already and we're, we're seeing it already with the anti-amyloid therapies. By and large, I think the standard of care is going to be a multidisciplinary individualized treatment plan that incorporates a more holistic view. It incorporates diet, lifestyle factors, symptomatic management, but also disease modification strategies and potentially even multitarget disease modifying strategies. I think there's a lot more work that we have to do, especially in in the non-Alzheimer's dementia field. But overall, we're becoming much better in refining our diagnostic impression and in treating some of the complications that arise in these very complex diseases.  Dr Grouse: I'm curious, with the future of dementia care and diagnosis being more of a precision medicine model, how do you think this will be possible in an aging population with already, I think, probably a limited access to neurologists even in current state? Dr Scholz: Yeah, this is- these are these are very challenging societal questions. Increasingly, you know, we can use modern technologies such as televisits for follow up, but also, you know, remote monitoring devices. We have to educate the next generation, we need more neurologists, we can't do it alone; but we also need to empower primary care doctors who are usually the first go-to person. And perhaps biomarker testing will become much more common even in the primary care setting. I think overall, you know, we can tackle it by educating the community, empowering participants in various clinical trials, and being flexible of embracing certain new technologies. Dr Grouse: Absolutely. I think that makes a lot of sense and hopefully this will be another call to arms to try to get the word out, get more access to neurology and more people interested and like you said, getting our other colleagues involved and being able to manage it as well.  Dr Scholz: Yeah.  Dr Grouse: I wanted to transition a little bit into learning more about you. How did you become interested in genetics of neurodegenerative dementias? Dr Scholz: Yeah, it's something, it's an interest that has grown gradually. I started out as a neuroscientist in in Austria, where I was fortunate to work with a group that was very strongly involved in Parkinson's disease care. And I was so thrilled to see patients, you know, treated with deep brain stimulation. But yet in the same clinic, I also saw the patients who were not eligible because they had atypical neurodegenerative diseases. And it's the realization that there is such a broad spectrum of diseases that we frankly don't understand very well, that we really need to work with, understand and hopefully develop the treatments with. That's really has resonated with me. And I've since then really built my entire career around it through different countries at the United Kingdom and the United States. And I'm very fortunate to work at the National Institutes of Health, where I can pursue a lot of these research passions and work with interesting patients and colleagues.  Dr Grouse: Well, I've learned a lot today, and I'm sure our listeners would agree. Thank you so much for joining us. It's really been a pleasure speaking with you.  Dr Scholz: Well, thank you so much for allowing me to contribute. And, you know, I hope the review article conveys a lot of the exciting developments in this really challenging field. But there's loads of hope that we will eventually get to the point to tackle these conditions.  Dr Grouse: I encourage all of our listeners to check out Dr Scholz 's article. It is a great overview of these conditions and the genetics and neuropathology underlining them. Again, thank you so much.  Dr Scholz: Thank you for having me. Dr Grouse: Again, today I've been interviewing Dr Sonia Scholz, whose article on genetics and neuropathology of neurodegenerative dementias appears in the most recent issue of Continuum on dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/AudioCME. Thank you for listening to Continuum Audio.

In this Women's History Minute, Dr. Alison Christy discusses the Cajal School of Neuropathology in Spain and emphasizes the importance of mentorship.

Stem cell models derived from patients with Parkinson's disease are valuable tools that are helping researchers around the world to better understand the underlying causes of neurodegeneration and to develop biomarkers and new therapies. To maximize the potential impacts of these tools, it is critical that they are developed and shared according to the principles of open science. In her interview, Dr. Birgitt Schüle discusses her work developing alpha-synuclein cell lines, challenges and opportunities in the field, and important considerations surrounding open science. She goes in-depth on how the cell lines were developed, characterized, and deposited with the American Tissue and Cell Collection (ATCC) with funding support from The Michael J. Fox Foundation, as well as how these cells can be used to fuel future discoveries. Birgitt is an Associate Professor in the Department of Pathology at Stanford University School of Medicine and Co-Director of the Alzheimer's Disease Research Center, Neuropathology, and Induced Pluripotent Stem Cell (iPSC) Core. This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Stem cell models derived from patients with Parkinson's disease are valuable tools that are helping researchers around the world to better understand the underlying causes of neurodegeneration and to develop biomarkers and new therapies. To maximize the potential impacts of these tools, it is critical that they are developed and shared according to the principles of open science. In her interview, Dr. Birgitt Schüle discusses her work developing alpha-synuclein cell lines, challenges and opportunities in the field, and important considerations surrounding open science. She goes in-depth on how the cell lines were developed, characterized, and deposited with the American Tissue and Cell Collection (ATCC) with funding support from The Michael J. Fox Foundation, as well as how these cells can be used to fuel future discoveries. Birgitt is an Associate Professor in the Department of Pathology at Stanford University School of Medicine and Co-Director of the Alzheimer's Disease Research Center, Neuropathology, and Induced Pluripotent Stem Cell (iPSC) Core. This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Send us a textIn Todays episode, we are privileged to host Dr. Helen Murray, a research fellow at the Centre for Brain Research at the University of Auckland. Dr. Murray is a distinguished neuroanatomist whose research delves into Chronic Traumatic Encephalopathy (CTE) and  other neuropathologies.With a remarkable publication record of over 30 peer-reviewed articles and more than 1,000 citations, Dr. Murray has been recognized with numerous academic awards and grants. Additionally, she brings a unique perspective as a high-level professional athlete, having played for the New Zealand Ice Fernz, making her international debut at the 2013 IIHF World Women's Championship and later serving as team captain in 2016.In today's episode, we will explore her significant contributions to the field and the ultimate implications of her work on concussion and brain health. -    Introduction How Dr Murray Become Involved In The Field of Neuropathology and mTBI/concussion/CTE-     What Is a Concussion & Sub Concussive Impacts? (5:30)-     What is CTE? (8:00)-     Conveying the Message (14:00)-     Signs, Symptoms, Stages and Probable CTE (18:45)-     Post-Concussion Symptoms vs Cognitive Impairment (21:10)-    Disease's That Cause Cognitive Decline (25:32)-    Diagnosis of CTE  (29:08)-    Future Research (31:50) Applying the Bradford hill criteria for causation to repetitive head impacts and chronic traumatic encephalopathyhttps://pubmed.ncbi.nlm.nih.gov/35937061/Neuropathology in chronic traumatic encephalopathy: a systematic review of comparative post-mortem histology literature: https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-022-01413-9X/Twitter: @hcmurray6https://www.brainbank.ac.nzhttps://concussionfoundation.orghttps://dementia.nz/dementia-in-contact-sport-athletes/

Journal editors Prof. Philip Smith and Dr. Geraint Fuller discuss the June 2024 issue of Practical Neurology, covering some of the interesting articles published this month. A number of difficult challenges and tradeoffs are featured, relating to recent men-only guidance for sodium valproate use, folic acid dosing for women with epilepsy, post-mortem brain donation, and sexual dysfunction caused by neurological medication. There is also some insight into the treatment of hepatic encephalopathy and congenital myasthenia. Read the issue: https://pn.bmj.com/content/24/3 Further reading: Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy. Vegrim HM, Dreier JW, Alvestad S, et al. JAMA Neurol. 2022;79(11):1130–1138. Please subscribe to the Practical Neurology podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3vVPClm) or Spotify (https://spoti.fi/4baxjsQ). We'd love to hear your feedback on social media - @PracticalNeurol. The PN podcast is produced by Letícia Amorim and edited by Brian O'Toole. Thank you for listening.

In Chronic Traumatic Encephalopathy (CTE) Part 1, we learned that CTE is a neurodegenerative disease caused by repetitive cumulative brain injury. Patients suffer from debilitating mental health symptoms and may even have suicidal thoughts or actions. Unfortunately, there is no treatment for this disease and it can only be official diagnosed at autopsy (after death). The only successful strategy to combat this illness is prevention. Unfortunately, this is an ongoing challenge as there is a lot we don't know about CTE but some features are clear. The largest risk factor for CTE is the duration of time participating in contact sport. In order to prevent CTE, the aim is to reduce life time exposure to repeated head impacts (either direct or indirect ie. significant acceleration and deceleration injuries). We also delve into grass-roots education aimed at informing school-aged children about concussion and brain health. This Medical Life podcast is available on all podcasting services and Spotify. Help support us at https://www.patreon.com/ThisMedicalLife ** Please note: General Practitioners in Australia, will be able to claim 2.25 CPD points after listening to this episode and part 1. Full details and registration on our GP CPD Points page. Our special guests: Amanda Green – wife to National Rugby League legend player and coach Paul Green who played 162 first-grade games and represented Australia. At the end of 2022, Paul was found unresponsive in his home. Paul's brain was donated to the Australian Sporting Brain Bank for examination where he was diagnosed with CTE. Paul was 49 years old. Associate Professor Michael Buckland – Head of the Neuropathology department at Royal Prince Alfred Hospital, founder and director of the Australian Sports Brain Bank (ASBB), co-director of the Multiple Sclerosis Australian Brain Bank, and Head of the Molecular Neuropathology Program at the Brain & Mind Centre. Doctor Stephanie Adams – Honorary Fellow in Sports & Brain Health at the University of Edinburgh. She is founder and director of ConcussEd which is an education program for school-aged children to learn about brain health. She is a retired rugby and equestrian athlete. This Medical Life podcast is available on all podcasting services and Spotify. Help support us at https://www.patreon.com/ThisMedicalLifeSee omnystudio.com/listener for privacy information.

In 2005, Dr Bennet Omalu would publish a report in the United States on the autopsy brain findings of a former professional footballer from the NFL. His conclusion was the former athlete suffered from Chronic Traumatic Encephalopathy (CTE); a disease caused by repeated brain injuries most likely due to sport. The response was swift and severe claiming that the findings were incorrect, the conclusions erroneous, and a retraction of this report was demanded. Surprisingly, this was not the first time medical literature has noted the link between sport, repeated head injuries and brain damage. The first publication was written in 1928 by Dr Harrison Martland who was the Chief Medical Examiner of Essex County in New Jersey. Harrison performed hundreds of autopsies on people with head injuries including boxers. He noted twenty-three examples of boxers with permanent brain damage that he called ‘punch drunk'. Other researchers found this was not limited to boxing but other contact sports such as football. Later, this condition became known as ‘Dementia pugilistica'. This disease has surged into the spotlight in the last decade due to a number of high-profile athletes who have been diagnosed with CTE. Unfortunately, both professional and amateur athletes are at risk. This condition also greatly impacts the family and friends of those who suffer from it. However, a great deal of misinformation also exists about the risks and causes of this disease. These two episodes (of which this is part 1) are designed to explain what we know, what we don't, and what can be done about this debilitating condition. This is the story of CTE, part 1. ** Please note: General Practitioners in Australia, will be able to claim 2.25 CPD points after listening to this episode and part 2. Full details and registration on our GP CPD Points page. Our special guests: Renee Tuck – sister of Shane Tuck who was a professional footballer in the Australian Football League (AFL) playing 173 games and a brief career as a boxer. Later in Shane's career, he suffered from mental health issues and in July 2020 took his own life. Shane was diagnosed with a severe form of CTE. He was only 38 years old. Associate Professor Michael Buckland – Head of the Neuropathology department at Royal Prince Alfred Hospital, founder and director of the Australian Sports Brain Bank (ASBB), co-director of the Multiple Sclerosis Australian Brain Bank, and Head of the Molecular Neuropathology Program at the Brain & Mind Centre. Associate Professor Linda Iles – Head of the Forensic Pathology Services at the Victorian Institute of Forensic Medicine (VIFM). VIFM is in partnership with the ASBB to send brain specimens for further examination/analysis for suspected CTE or other neurodegenerative diseases. This Medical Life podcast is available on all podcasting services and Spotify. Help support us at https://www.patreon.com/ThisMedicalLife  See omnystudio.com/listener for privacy information.

In this podcast we venture into the complex world of neuropathology. Our guests talk about their research, and uncover why neuropathology is so important to understanding dementias. During the discussion they also share a behind scenes glimpse into the workings of a brain bank, explore how brain tissue is used and how it can inform drug trials and personalised care, and provide a shock revelation about the difference between diagnosis in life, and what the brain shows after death. From groundbreaking discoveries to the cutting-edge techniques transforming how we understand and approach brain health, this episode is an essential listen for anyone intrigued by the science of the brain and the fight against dementia. Dr Kamar Ameen-Ali, Senior Lecturer at Teesside University hosts our expert guests, Tammaryn Lashley, Professor of Neuroscience from University College London, Dr Daniel Erksine, Senior Lecturer in Neurodegenerative Pathology and Newcastle University and Dr Laura Palmer, Manager of the South West Dementia Brain Bank at University of Bristol. -- For more information on our guests work visit: • South West Brain Bank - https://bit.ly/49VRVUD • Queen Square Brain Bank - https://bit.ly/3SEskbH • Brains for Dementia Research - https://bit.ly/3SICEiX • Newcastle Neuro Lab - https://bit.ly/3SIb45d -- Full biographies on all our guests and a transcript can be found on our website www.dementiaresearcher.nihr.ac.uk Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you'll find a video version of this podcast on our website & YouTube channel, with captions https://youtu.be/y-Hqt30wJtI -- This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. -- Follow us on Social Media: www.instagram.com/dementia_researcher/ www.facebook.com/Dementia.Researcher/ twitter.com/demrescommunity bsky.app/profile/dementiaresearcher.bsky.social www.linkedin.com/company/dementia-researcher

Hosts: Carolyn McMakin, MA, DC Kim Pittis, LCSP, (PHYS), MT Dr. Carol and Kim delve deep into the benefits and mechanics of FSM and various other assistive tools in managing pain and chronic conditions. They highlight numerous real-life cases to exemplify how FSM treatment brings relief to patients, and uniquely addresses problems often overlooked by traditional practices. They share insights into the intersection of physical and emotional components of healing, stressing on the importance of patient autonomy, and focusing on the root cause rather than just the symptoms.   00:30 Importance of Taking a Pause 00:56 Case Study: Patient with Abdominal Pain 07:55 The Importance of Accurate Diagnosis 16:12 The Role of Anxiety in Muscle Splinting 28:52 The Power of Frequency Specific Microcurrent 18:45 The Importance of Patient Safety and Comfort 25:00 The Impact of Positive and Negative Experiences on Treatment 26:57 Patient Case Study: Pain Management and Emotional Stages 29:59 The Importance of Patient Education in the Healing Process 31:57 Discussion on Disc Herniations and Bulges 33:15 Q&A Session: Addressing Viewer Questions 40:34 The Role of Exercise in Healing 42:48 Dealing with Anger in Dementia Patients 47:22 Closing Thoughts: Patient Advocacy and Self-Care # Health advice # Frequency specific microcurrent # FSM therapy # Advanced health procedures # Chronic pain management # Physical therapy techniques # Medical procedures # Healthcare # Pain avoidance strategies # Dementia management # Alzheimer's conversations # Vagus nerve # Neuropathology # Mental health  

Small fiber neuropathy is one of those conditions in neurology that can feel frustratingly intangible. Even for patients with severe neuropathic pain and autonomic symptoms, in about half of cases, the usual lab testing doesn't reveal a cause. There's increasing evidence that autoimmunity may be a factor in some of these cases of idiopathic small fiber neuropathy, but how to test and who to treat with immunosuppression is less clear. Our guest today, Anne Louise Oaklander, is an Associate Professor of Neurology at Massachusetts General Hospital and an Assistant in Neuropathology. She's known for her work on small fiber neuropathies and in this episode we'll talk about new autoantibodies associated with small fiber neuropathy and where we are in treating this challenging condition. Series 5, Episode 4 Featuring: Guest: Dr. Anne Louise Oaklander Interviewer: Dr. Adeline Goss Disclosures: None

Thank you Eric KO, MS III, for developing this podcast. Thank you Khamil Durodola, OMS III, for being the sidekick in this production! We review high yield information briefly at onset about genetic testing concepts that may be tested on the Shelf. We follow this with a discussion about how neuropathology has quit being "the graveyard of neuropathology" and entered a realm that is remarkably exciting. This includes a great set of discussions that describe how we understand the field currently based on our reading of the papers reviewed. We also discuss some of the techniques that are now being used--to the best of our understanding. We enjoyed our discussion and hope you do too! Thank you to the immortal Jordan Turner for creating the perfect bumper music!

Science is all about rigorous testing, empirical evidence, and painstaking documentation, right? But even in the most state-of-the-art labs, you'll find researchers who hold on to quirky rituals, lucky charms, or, dare we say it, superstitions. In this podcast, Dr Yvonne Couch, Associate Professor at University of Oxford hosts a discussion that romps through the lighter side of scientific research by exploring the wonderful world of lab superstitions. From lucky pipettes to forbidden phrases, we're about to uncover the unofficial 'do's and don'ts' that researchers swear by, or at least, swear make for good anecdotes. -- This shows guests are: Dr Kamar Ameen-Ali, Lecturer in Biomedical Science at Teeside University. In addition to teaching, Kam is interested in How neuroinflammation following traumatic brain injury contributes to the progression of neurodegenerative diseases (such as Alzheimer's disease) that lead to dementia. Dr Soraya Meftah, Postdoctoral Research Fellow in the UK Dementia Research Institute at The University of Edinburgh. Soraya works in the space of Neurophysiology of dementia (synaptic, neuronal, network dysfunction). Tabitha Broadbelt just completed her PhD at The University of Edinburgh and is now a Postdoctoral Researcher at the MRC Brain Network Dynamics Unity at University of Oxford. In the Dupret Group, Tabitha uses optogenetics and large-scale single-unit recordings combined to study memory-guided behaviour. Dr Lauren Walker is an Alzheimer's Research UK Fellow at Newcastle University. Lauren complete her undergrad degree in Physiological Sciences, and worked in a technical role for 7 years before being inspired to return to study a PhD. Lauren now works in Neuropathology of Lewy body dementia and Alzheimer's disease. -- Full biographies on all our guests and a transcript can be found on our website https://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you'll find a video version of this podcast with full captions on our YouTube Channel -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.

Leland Stillman, MD, has dedicated his career to exploring holistic, natural, and functional medicine as a means to achieve genuine health instead of merely addressing symptoms. With a background in Internal Medicine, Dr. Stillman combines cutting edge medical research with ancient healing practices to reach optimal health. He offers valuable knowledge and guidance on a wide range of subjects related to healing and well-being.STILLMAN WELLNESS SPECIAL OFFER: 50% off courses10% discount on eligible offers: ROGERLeland StillmanLeland Stillman, MD | Linktree​​Leland Stillman (@stillmanmd) • Instagram photos and videosLeland Stillman, MD (@StillmanMD) / XLeland Stillman - YouTube*If you are in crisis or believe you have an emergency, please contact your doctor or dial 911. If you are contemplating suicide, call 1-800-273-TALK to speak with a trained and skilled counselor.RADICALLY GENUINE PODCASTDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / X (Twitter)Substack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically Genuine—-----------FREE DOWNLOAD! DISTRESS TOLERANCE SKILLS—----------ADDITIONAL RESOURCES8:30 - What is Functional Medicine? | IFM.22:00 - Endocrine disorders: Causes, types, and diagnosis25:30 - Stress Response: What's the Difference Between Eustress and Distress?26:30 - Allostatic Load - an overview | ScienceDirect Topics27:30 - Air Pollution and Criminal Activity: Evidence from Chicago Microdata | NBER30:00 - What is Heart Rate Variability (HRV) & why does it matter? | Firstbeat Blog32:30 - Stillman Wellness33:00 - GYM Laird Strength & Conditioning34:20 - Oura Ring Fitness Tracker - Dr. Stillman Substack42:00 - Influence of mild cold on 24 h energy expenditure, resting metabolism and diet-induced thermogenesis | British Journal of Nutrition | Cambridge Core48:30 - Benefits of Eating One Meal a Day | David Sinclair | How To Eat Healthy52:00 - Nutrition and Your Mind - The Psychochemical Response: Dr. George Watson, W. D. Currier, M.D.52:15 - Is This Your Child?: Rapp M.D., Doris53:00 - The Neuropathology of Gluten-Related Neurological Disorders: A Systematic Review - PMC53:30 - Feingold Diet: Treating ADHD By Removing Food Additives55:00 - Quantum theory-based physical model of the human body in TCM57:00 - The Body Electric - Robert O. Becker1:06:00 - The Influence of Ocular Light Perception on Metabolism in Man and in Animal (Topics in Environmental Physiology and Medicine)

Molecular Neuropathologist & PI Katja Kobow explains her research into unraveling the intricate interplay between epigenetic alterations and the development of epilepsy, specifically in the context of the adult post-mitotic brain. ------------------------------------------

Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD

Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD

Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD

Go online to PeerView.com/NEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age, and increasing in prevalence as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD. Now, after almost two decades without a new AD treatment, recent advances in DMTs, including the accelerated approval from the FDA of two amyloid-targeting therapies (ATTs) and a third in late-stage development, have opened the door to the possibility of reductions in disease progression and improved patient outcomes. In order for these treatments to be successful, initiation in the prodromal or early symptomatic stages of AD is critical. Fortunately, significant advances have been made in the development and validation of molecular imaging techniques that may aid in an early diagnosis. It is therefore imperative that clinicians remain aware of the evolving role of molecular imaging tools (eg, amyloid PET, FDG PET, tau PET) and PET quantification techniques in the early diagnosis of AD, and are prepared to integrate these diagnostic tools into clinical practice. At a recent PeerView educational event, a panel of AD experts illustrated how to integrate validated and emerging neuroimaging biomarkers and quantitative measures into clinical practice to facilitate AD diagnosis. Through a case-based discussion, the faculty offered learners an in-depth look at the complex diagnostic challenges associated with early AD and mild cognitive impairment, and provided practical guidance on effectively and appropriately incorporating these strategies into patient care. You can now watch this on-demand version of the event! Upon completion of this activity, participants should be better able to: Employ molecular imaging tools to optimize the timely and accurate neuropathological diagnosis of AD; and Apply quantitative analysis to augment the visual interpretation of PET imaging in AD

Drive with Dr. Peter Attia Key Takeaways Check out The Drive Episode Page & Show NotesRead the full notes @ podcastnotes.org View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Tommy Wood is an Assistant Professor of Pediatrics at the University of Washington, where he studies brain injury and how lifestyle choices and environmental factors contribute to brain health, cognitive function, and chronic disease. In this episode, Tommy delves into the complexities of age-related cognitive decline and explores interventions to counteract it. Drawing from his experience working with Formula 1 drivers, he highlights the connection between cognitive function and the right type of demands and training leading to improvement. Next, he explores the various theories on the different types of pathology in dementia and neurodegeneration. He makes the case that a large fraction of dementia is preventable through lifestyle choices and nutrient status, and provides an in-depth overview of interventions and supplements that support cognitive function. Finally, he provides a comprehensive overview of head injuries, including concussions and traumatic brain injuries (TBIs), discussing symptoms, how to mitigate damage following an incident, and long-term management. We discuss: Tommy's professional work, unique skill sets, and interests [3:00]; Age-related decline in cognitive function and memory [5:45]; Improving brain function with the right level and type of demand [20:15]; Formula 1 as a model for how to perform under high cognitive demand and how to increase multitasking capacity [31:30]; Advice for the person reaching middle life looking to mitigate cognitive decline [37:45]; Tasks and activities that support and improve cognitive function [45:30]; Neuropathology of Alzheimer's disease: exploring the role of amyloid and tau proteins [49:30]; Why Tommy believes dementia research funding should be focused on environmental and lifestyle-based risk factors [1:05:15]; Benefits of lowering homocysteine and boosting omega-3's, and evidence-based supplements that support cognitive function [1:09:00]; A unifying theory of dementia [1:20:45]; How muscular strength can help with both the prevention and survivability of dementia [1:24:15]; Head injuries: comparing concussions against traumatic brain injuries (TBIs), mitigating the damage after an incident, and the long-term management of head injuries [1:29:15]; Is hyperbaric oxygen treatment helpful after a TBI? [1:45:45]; Supplements that aid recovery from a TBI: creatine, DHA, and choline [1:49:30]; Demands faced by F1 drivers, and testing interventions to improve their performance [1:57:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Tommy Wood is an Assistant Professor of Pediatrics at the University of Washington, where he studies brain injury and how lifestyle choices and environmental factors contribute to brain health, cognitive function, and chronic disease. In this episode, Tommy delves into the complexities of age-related cognitive decline and explores interventions to counteract it. Drawing from his experience working with Formula 1 drivers, he highlights the connection between cognitive function and the right type of demands and training leading to improvement. Next, he explores the various theories on the different types of pathology in dementia and neurodegeneration. He makes the case that a large fraction of dementia is preventable through lifestyle choices and nutrient status, and provides an in-depth overview of interventions and supplements that support cognitive function. Finally, he provides a comprehensive overview of head injuries, including concussions and traumatic brain injuries (TBIs), discussing symptoms, how to mitigate damage following an incident, and long-term management. We discuss: Tommy's professional work, unique skill sets, and interests [3:00]; Age-related decline in cognitive function and memory [5:45]; Improving brain function with the right level and type of demand [20:15]; Formula 1 as a model for how to perform under high cognitive demand and how to increase multitasking capacity [31:30]; Advice for the person reaching middle life looking to mitigate cognitive decline [37:45]; Tasks and activities that support and improve cognitive function [45:30]; Neuropathology of Alzheimer's disease: exploring the role of amyloid and tau proteins [49:30]; Why Tommy believes dementia research funding should be focused on environmental and lifestyle-based risk factors [1:05:15]; Benefits of lowering homocysteine and boosting omega-3's, and evidence-based supplements that support cognitive function [1:09:00]; A unifying theory of dementia [1:20:45]; How muscular strength can help with both the prevention and survivability of dementia [1:24:15]; Head injuries: comparing concussions against traumatic brain injuries (TBIs), mitigating the damage after an incident, and the long-term management of head injuries [1:29:15]; Is hyperbaric oxygen treatment helpful after a TBI? [1:45:45]; Supplements that aid recovery from a TBI: creatine, DHA, and choline [1:49:30]; Demands faced by F1 drivers, and testing interventions to improve their performance [1:57:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Dr. Riddle is a Senior Pathologist for Ruffolo, Hooper, and Associates, providing services at Tampa General Hospital / USF Health, where she is also the Pathology Residency Site Director. There she does General Anatomic Pathology with a focus in Bone & Soft Tissue, Gastrointestinal Pathology, Neuropathology, and Dermatopathology. She is also Associate Professor and Associate Residency Program Director for the USF Health Department of Pathology and Cell Biology. Dr. Riddle is heavily involved in organized medicine. She has been active in the AMA since 2002, serves on the board of the Florida Society of Pathology (FSP) and COLA, and sits on committees for the College of American Pathologists, the Digital Pathology Association, USCAP, FSP, and her county medical society. She has a specific interest in digital pathology, informatics, high reliable medicine, and creating a culture of quality and patient safety, as well as varied research endeavors.  Dr. Riddle has been honored with several awards including the ASCP 2018 “40 under Forty”, the Pathologist Magazine's “Power List”, and the 2021 CAP Resident Advocate Award.Twitter: @NRiddleMD

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: January 28, 2021 To quote Donald Rumsfeld, “there are things we know we know…. we know there are some things we do not know... But there are also unknown unknowns—the ones we don't know we don't know…it is the latter category that tends to be the difficult ones.” In neurology, the agnosias are not that dissimilar from Rumsfeld's 'unknown unknowns.' In this week's program, we discuss the nosology and nomenclature for the agnosias, the localization, and the importance of recognizing one. Produced by James E Siegler. Music courtesy of Dr. Turtle, Grossman, Ewell and Grainger, Marco Trovatelli, and Purple Planet Music. The opening theme was composed by Jimothy Dalton. Sound effects by Mike Koenig and Daniel Simion. Unless otherwise mentioned in the podcast, no competing financial interests exist in the content of this episode. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. Be sure to follow us on Twitter @BrainWavesaudio for the latest updates to the podcast. REFERENCES Biran I, Coslett HB. Visual agnosia. Curr Neurol Neurosci Rep 2003;3(6):508-12. PMID 14565906Coslett HB. Apraxia, neglect, and agnosia. Continuum (Minneap Minn) 2018;24(3, Behavioral Neurology And Psychiatry):768-82. PMID 29851877Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The pathophysiology of 'happy' hypoxemia in COVID-19. Respir Res 2020;21(1):198. PMID 32723327Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020;92(6):552-55. PMID 32104915Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 2020;19(11):919-29. PMID 33031735Milner AD, Perrett DI, Johnston RS, et al. Perception and action in 'visual form agnosia'. Brain 1991;114 (Pt 1B):405-28. PMID 2004249Zeki S, Ffytche DH. The Riddoch syndrome: insights into the neurobiology of conscious vision. Brain 1998;121 ( Pt 1):25-45. PMID 9549486We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

Go online to PeerView.com/UHK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Early detection and diagnosis of Alzheimer's disease (AD) can give patients more control over their health and future and can lead to improved outcomes. Significant advances have been made in the development of neuroimaging biomarkers, including amyloid PET and tau PET, that may aid in the early diagnosis of AD, facilitate patient selection for treatment, and monitor therapeutic response. With the anticipated growth in patients with AD around the globe and evolving developments in AD assessment and treatment, radiologists and nuclear medicine physicians are poised to play an increasingly vital role throughout AD management. In this activity, based on a recent live symposium, a panel of expert faculty discusses the importance of a timely and accurate diagnosis of AD, as well as recent research related to the evolving and complementary role of neuroimaging and fluid biomarkers in the early diagnosis and ongoing management of AD. Upon completion of this activity, participants should be better able to: Recognize the importance of making a timely and accurate neuropathological diagnosis of AD; Apply current and emerging diagnostic tools to optimize the neuropathological diagnosis of AD early in the disease course; and Identify the advantages and limitations associated with PET, cerebrospinal fluid (CSF), and plasma biomarkers

Go online to PeerView.com/UHK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Early detection and diagnosis of Alzheimer's disease (AD) can give patients more control over their health and future and can lead to improved outcomes. Significant advances have been made in the development of neuroimaging biomarkers, including amyloid PET and tau PET, that may aid in the early diagnosis of AD, facilitate patient selection for treatment, and monitor therapeutic response. With the anticipated growth in patients with AD around the globe and evolving developments in AD assessment and treatment, radiologists and nuclear medicine physicians are poised to play an increasingly vital role throughout AD management. In this activity, based on a recent live symposium, a panel of expert faculty discusses the importance of a timely and accurate diagnosis of AD, as well as recent research related to the evolving and complementary role of neuroimaging and fluid biomarkers in the early diagnosis and ongoing management of AD. Upon completion of this activity, participants should be better able to: Recognize the importance of making a timely and accurate neuropathological diagnosis of AD; Apply current and emerging diagnostic tools to optimize the neuropathological diagnosis of AD early in the disease course; and Identify the advantages and limitations associated with PET, cerebrospinal fluid (CSF), and plasma biomarkers

Today my guest is Pathologist Dr Greg Fuller What we discuss with Dr Fuller: How he became interested in neuropathology How studying English has an influence on his work now His early mentors and how they helped steer his career The concept of Diagnostic Medicine and why it is important The 8 Data Sphere Model and how it is used to make a diagnosis How the methods of Sherlock Holmes are similar to Diagnostic Medicine Some of the highlights of Dr Fuller's career Links for this episode: Health Podcast Network  LabVine Learning The ConfLab from LabVine Dress A Med scrubs   Dr Greg Fuller on Twitter Dr Fuller on the Follow Your Path Podcast  MD Anderson Faculty Profile Gregory Fuller ‘76, Distinguished Former Student 2022 - Texas A&M The Memoirs of Sherlock Holmes   People of Pathology Podcast: Website Twitter Instagram

Dr. Areli K. Cuevas-Ocampo is a Medical Doctor who follows a raw-vegan lifestyle. She is Board-certified in Anatomic-Clinical Pathology and Neuropathology and is certified in Plant-Based Nutrition by the University of Winchester. She is also a member of the Plant-Based Health Professionals of UK. Dr. Cuevas-Ocampo is interested in raising public awareness on how to modify epigenetic risk factors like diet, in particular with a fruit-based raw-vegan approach; we can prevent, improve, or even reverse most of the modern diseases of Western societies. Find Dr. Areli at the main social media platforms @RawVeganDoctor on Instagram, Youtube, Facebook, and Twitter.Show notesDr. Areli on InstagramDr. Areli on FacebookDr. Areli's current YouTube ChannelDr. Areli's old YouTube ChannelDr. Areli on TwitterBearded Brothers BarsWhat we talked about:3:40- Introduction to Dr. Areli9:30- Her transition to a raw lifestyle12:10- What eating raw means16:30- Sprouting18:10- What Dr. Areli's transition to raw lifestyle has looked like20:30- Difference between high raw and fully raw27:35- Oils34:40- Top three tips for eating raw38:10- Reasons that Dr. Areli sees people not succeed with a raw diet41:40- What a day in the life of eating looks like for Dr. Areli50:25- Wrap-upConnect with Stacey:Stacey on InstagramStacey's WebsiteJoin The Herban Farmacy Facebook GroupShop BeautycounterSandyBoy Productions Shows:Why is Everyone Yelling?The Illuminate PodcastI'll Have Another with Lindsey HeinThe Ready to Run PodcastSponsors:Green Growers Organic Elderberry Syrup & Elderberry KitsUse code "Holistic" for 20% off and free shipping

On October 13, 2022 we sat down to chat with Mel B. Feany about the molecular processes underlying the neuropathology of alpha-synuclein and Parkinson's disease. We focused on her findings implicating the actin cytoskeleton as an intermediary in mitochondrial dysfunction and other cellular mechanisms that contribute to pathology and cell death. Guest: Mel B Feany, Department of Pathology, Division of Neuropathology, Brigham and Women's Hospital and Harvard Medical School. Participating: Chris Gamblin, Department of Neuroscience, Developmental and Regenerative Biology, UTSA Hyoung-gon Lee, Department of Neuroscience, Developmental and Regenerative Biology, UTSA Host: Charles Wilson, Department of Neuroscience, Developmental and Regenerative Biology, UTSA

Click to sign up for our Compensation Negotiation Workshop: https://www.eventbrite.com/e/compensation-negotiation-workshop-tickets-399319343907?utm-campaign=social&utm-content=attendeeshare&utm-medium=discovery&utm-term=listing&utm-source=cp&aff=escb Lexi and Libby sit down with Kimberly Fiock in today's episode. Kimberly studies brain diseases in a lab and is working toward earning her PHD. With a bachelor's degree in neuroscience & psychology, and a masters in pathology, Kimberly shares her passions and recommendations for how to navigate a PHD program. This episode also touches on mental health. Kimberly shares her personal experiences with having OCD and Bipolar, and gives advice for how to cope with mental health in a high stress STEM field. Follow Kimberly on Instagram: https://www.instagram.com/thepathphd/?hl=en More pathology resources that were talked about in this episode: https://people.rit.edu/~gtfsbi/Symp/highschool.htm https://people.rit.edu/~gtfsbi/Symp/Neuroscience.htm https://people.rit.edu/~gtfsbi/Symp/summer.htm#skip Submit your review to the google form here to be entered in our visa gift card giveaway: https://linktr.ee/mybestfriendsanengineer

This week, Jessica talks with Dr. Arie Perry who is a physician & classical singer. Arie started singing in a rock band in high school (inspired by Journey and Rush) and then he caught the classical music bug. He's performed as a lyric tenor with a number of ensembles including the San Francisco City Chorus, Oakland City Chorus, and American Bach Soloists. Arie is also a physician and the Chief of Neuropathology at UCSF. Combining his vocal talents and medical expertise, he released an album on Spotify called Neuropathology Songs to help his students remember salient features of common neurological disorders. Check out Arie's neuropathology songs on YouTube Are you a high achiever, a leader in your workplace, a person with many interests, maybe even an Ampersand? Well, guess what? Jessica works with people just like you. Jessica can help you navigate change, stay true to your values, and thrive as a leader. Learn more at jessicawan.com. She reads every single message. Credits Produced and Hosted by Jessica Wan Co-produced, edited, and sound design by Naomi Tepper Theme music by Denys Kyshchuk and Stockaudios from Pixabay

In this episode, our host Dr. Swikrity U Baskota (@baskotacytopath), founder of www.matchtopath.com discusses the Electronic Residency Application Service® (ERAS®) pathology residency process with our expert panelists. The speakers include Dr. Thomas Cummings (@tjcmd888) Professor of Pathology, Director of Neuropathology and Ophthalmic Pathology and Residency Program Director at Duke University, North Carolina,  Dr. Carlos Pagan (@CAPaganPath) Assistant Professor of Surgical and Molecular Pathology and Residency Program Director at Columbia University, Dr. Clarissa Jordan (@pathcejmd), PGY-3 resident at Mayo Clinic, Future hematopathology fellow at Mayo Clinic and Dr. Melissa Meija Bautista (@Melissa_MB91), PGY-4 resident at Northwestern University, Future Pediatric pathology Fellow at Boston Children's Hospital and future neuropathology fellow at Northwestern University, Chicago.    Join us to learn more about the 2023 ERAS application timeline. What is a program looking for in a candidate's application? How can you strengthen your ERAS CV, and personal statement? How can you ensure your application is ready before the deadline...and many other tips shared by our expert guests!    Reference: ERAS® 2023 Residency Timeline | Students & Residents (aamc.org)   MatchtoPath: www.matchtopath.com Twitter: @matchtopath;  Instagram, Facebook and LinkedIn: matchtopath   

Ladies n' Genminminminmin (er, min...) we have Clergy in 'The Clearing'!Please welcome my very dear and lovely old friend The Reverend Olivia Coles. A real life "Vicar of Dibley" here in The Good Listening To Podcast: The Story Behind Your Story Show! recorded as a FaceBook LIVE!"More tea Vicar?""No, but I'll have another one of those Rock Cakes. Those are the buggers that made me fart..." erm, etc!Hurrah!Olivia Coles is the Vicar of Whittlesford, in Cambridgeshire. Her late father, Jeremy, was himself a Vicar, her mother Margaret was a Trauma Counsellor (and still with us). Her husband, Alasdair, is a Professor of Neuropathology at Cambridge University and he too is ordained. Their son Alex is a Northampton Saint! (He plays Rugby professionally - he has not been canonised!) Their social worker daughter, Kana, is currently specialising in Domestic Abuse. More about Olivia:Olivia herself has enjoyed a lot of training, a lot of counselling and a lot of open-house life experience in Zambia and Peru as well as in the UK. Her faith is God is beacon-like without being off-putting. Her sincerity shines through her conversation. Some might say she exhibits evidence of low self-esteem. Others might more charitably recognise her attractive humility and wonderful work ethic. The Reverend Olivia Coles loves people. She loves listening to them. She loves sharing their joy at christenings and weddings, as well as in old age, supporting their grief at funerals and wakes. Olivia takes her job very seriously - but not herself. (She once sat in a bath of porridge as a student for a whole day to raise money for charity!) For Olivia, all relationships are of paramount importance. Primarily, of course, her relationship with God and then follow all her other relationships - with her extended family and many friends, her parishioners and the wider community, including refugees arriving soon under her roof from Ukraine. She loves walking with her dog, especially on the seashore, describing the sea itself as ‘God's paintbox'. Olivia has no doubt whatsoever that God is always with us. She has no doubt whatsoever that God loves us unconditionally. Her best advice resonates the recommendation of all 12 Step fellowships: “Let go and let God!”If you are world-weary and cynical, you may find Olivia's ideas at best, naive and at worst, simplistic. But remember, it is both ignorant and arrogant to reject them without even listening to them. We invite you therefore to open your ears, open your mind, open your heart. Who knows how affected you may be by Olivia's quiet enthusiasm? Do you remember the story of St Paul on the road to Damascus?  Think about it!Reg Starkey - Health Triangle Magazine

Katja Kobow is the most recent winner of the Michael Prize, an international award in epilepsy research. Her work focuses on epigenetics and epilepsy, a field that has grown exponentially in only the past 10 to 15 years. Dr. Kobow talked about her research and its potential for epilepsy diagnosis and treatment.Epigenetics is the bookmarking system or the data management system of our genome. It decides which part of the genome is read, and when to read it. The epigenome is what makes the genome versatile in terms of regulating gene expression.Epigenetics is crucial for all aspects of brain development and function. It's also reversible, which has exciting implications for anti-epileptogenic therapies.  Dr. Kobow is assistant professor at the Institute of Neuropathology at the University Hospital Erlangen, Germany. Selected recent publications: DNA methylation-based classification of malformations of cortical development in the human brain (Acta Neuropathologica, 2022)Molecular diagnostics in drug-resistant focal epilepsy define new disease entities (Brain Pathology, 2021)Epigenetics explained: a topic “primer” for the epilepsy community by the ILAE Genetics/Epigenetics Task Force (Epileptic Disorders, 2020)The Michael Prize is awarded in odd-numbered years; entries for the 2023 prize are now open and accepted until December 31, 2022.---This episode was reported, edited, and produced by Nancy Volkers.Contact us with feedback or episode ideas at podcast@ilae.orgSharp Waves content is meant for informational purposes only and not as medical or clinical advice. The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Twitter, and Instagram. ILAE website | Facebook | InstagramTwitter feeds: English | French | Japanese | Portuguese | Spanish | ILAE-YES Support the showSharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Twitter, and Instagram.

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Patricia Pittman, oncologic pathologist and neuropathologist at Caris Life Sciences, to discuss the latest in neuropathology. For more information, please visit: www.CarisLifeSciences.com

It's a common sight on Sunday afternoon. The snacks are gathered. The couch cushions are plumped. The beer is cold. Across the screen, twenty-two people in tight white pants and polished helmets trot across the screen. But behind the shiny exterior of football, America's favorite pastime, lies a dark secret - chronic traumatic encephalopathy (a word I am incapable of pronouncing). A neurodegenerative disease characterized by psychological, behavioral, and cognitive changes, CTE and repeated head trauma has been linked to rage behaviors and increased aggression. In fact, Aaron Hernandez, a former NFL player was posthumously diagnosed with advanced CTE, potentially providing a "why" for his brutal murder of Odin Llyod. If you have any comments, questions, concerns, queries, or complaints, please email me at NeuroscienceAmateurHour@gmail.com or DM me at @NeuroscienceAmateurHour on Instagram. Citations and relevant papers below: NFL Helmet Challenge Raises the Bar for Helmet Technology and Performance, Awards $1.55 Million in Grant Funding to Help New Models Get on Field Faster. NFL.com. https://www.nfl.com/playerhealthandsafety/equipment-and-innovation/innovation-challenges/nfl-helmet-challenge-raises-the-bar-for-helmet-technology-and-performance-awards Published 2021. Built By Data: NFL Helmet Innovation. NFL.com. https://www.nfl.com/playerhealthandsafety/equipment-and-innovation/engineering-technology/built-by-data-nfl-helmet-innovation. Published 2021. Heintz E, Breaux L, Lewis A, Foreman J. Determinants of Missed Games Following Concussions in the National Football League. Front Sports Act Living. 2020;2. doi:10.3389/fspor.2020.595445Tator C. Concussions and their consequences: current diagnosis, management and prevention. Can Med Assoc J. 2013;185(11):975-979. doi:10.1503/cmaj.120039Mez J, Daneshvar D, Kiernan P et al. Clinicopathological Evaluation of Chronic Traumatic Encephalopathy in Players of American Football. JAMA. 2017;318(4):360. doi:10.1001/jama.2017.8334McKee A, Stein T, Kiernan P, Alvarez V. The Neuropathology of Chronic Traumatic Encephalopathy. Brain Pathology. 2015;25(3):350-364. doi:10.1111/bpa.12248Asken B, Sullan M, DeKosky S, Jaffee M, Bauer R. Research Gaps and Controversies in Chronic Traumatic Encephalopathy. JAMA Neurol. 2017;74(10):1255. doi:10.1001/jamaneurol.2017.2396Turner R, Lucke-Wold B, Robson M, Lee J, Bailes J. Alzheimer's disease and chronic traumatic encephalopathy: Distinct but possibly overlapping disease entities. Brain Inj. 2016;30(11):1279-1292. doi:10.1080/02699052.2016.1193631Giza C, Hovda D. The New Neurometabolic Cascade of Concussion. Neurosurgery. 2014;75:S24-S33. doi:10.1227/neu.0000000000000505Haislop T. Aaron Hernandez timeline: From murders and trials to prison suicide. Sportingnews.com. https://www.sportingnews.com/us/nfl/news/aaron-hernandez-timeline-murders-trials-prison-suicide/1886y82a8bgyx123qxcgg04lb5. Published 2020. Support the show (https://www.patreon.com/neuroscienceamateurhour)

Dr. Günter Hoglinger discusses the article he recently published in the Movement Disorders journal on tau imaging in a cohort of corticobasal syndrome patients, along with amyloid PET and CSF analysis to differentiate the neuropathological entity underlying the clinical manifestations. Read the article

Dr. Omalu received his MB, BS [M.D.] degree from the University of Nigeria in 1991. He received his MPH [Masters in Public Health] degree in Epidemiology from University of Pittsburgh in 2004. He also received his MBA [Masters in Business Administration] degree from Carnegie Mellon University in 2008. Dr. Omalu holds four board certifications in Anatomic Pathology, Clinical Pathology, Forensic Pathology and Neuropathology. Dr. Omalu is also board certified in Medical Management and is a Certified Physician Executive [CPE]. Dr. Bennet Omalu, identified a disease he called Chronic Traumatic Encephalopathy [CTE] in the brains of deceased athletes and military veterans; and received the “Distinguished Service Award” in 2016, which is the highest award of the American Medical Association. In December 2015, Sony Pictures produced and released a major Hollywood film titled “Concussion” on Bennet's life and work. Will Smith played Dr. Omalu in the film. Bennet's memoir “Truth Doesn't Have a Side” was published in 2017 by Zondervan, HarperCollins. Dr. Bennet Omalu is currently the President and Medical Director of Bennet Omalu Pathology. --- Send in a voice message: https://podcasters.spotify.com/pod/show/mastermine-mrg/message

Hi Friends! Welcome to another episode of the diversify in path podcast. This podcast explores how  investing in diversity  can lead to  a high return of investment in pathology and laboratory medicine by learning from the knowledge and experiences of  diverse voices within in our field.  My next guess is Dr. William Humphrey Dr. William Humphrey is a writer and 3rd-year resident pathologist at the University of Vermont Medical Center. He is involved in Global Health and Pathology Clinical Informatics at the national level and has accepted a Neuropathology fellowship at the Mayo Clinic. His writings on the medical trainee experience as well as his own personal and professional path can be found in outlets such as Academic Medicine and Path Elective. He recently finished work on a novel, his first work of fiction, and  launched his own blog .Twitter:@TheDoctorIsILLInstagram: TheDoctorisILLWebsite:  TheDoctorIsILL.com

Today's episode is all about a raw vegan diet! We are speaking with Dr Areli who has been following a raw vegan diet, low in fat for a number of years and thriving. We discuss her journey and also provide tips on following a raw vegan diet. Free consultation with High Carb Health: https://www.highcarbhealth.com/healthsurvey/ About Dr Areli: Dr. Areli K. Cuevas-Ocampo is a Medical Doctor who follows a raw-vegan lifestyle. She is Board-certified by the American Board of Pathology in Anatomic-Clinical Pathology and Neuropathology and she recently was granted a "Plant-Based Nutrition" certificate by the University of Winchester and Plant-Based Health Professionals of UK. Dr. Cuevas-Ocampo is interested in raising public awareness on how modifying epigenetic risk factors like diet, in particular with a fruit-based raw-vegan approach; we can prevent, improve, or even reverse most of the modern diseases of Western societies. Besides looking at diseases under the microscope, examining brains, and doing autopsies, Dr Areli is an educator and coach, with expertise in raw-food nutrition. She combines her medical background, plant-based knowledge, and her own experience as a raw-foodist to teach people about the incredible benefits of incorporating more raw fruits and vegetables into our diets. Follow her on social media @RawVeganDoctor on Instagram, Youtube, Facebook, and Twitter.

Hi Friends, This is Dr. Michael Williams,  and welcome to another episode of the diversify in path podcast.This podcast explores how  investing in diversity  can lead to  a high return of investment in pathology and laboratory medicine by learning from the knowledge and experiences of  diverse voices within in our field.  My next guest is Dr. Eddie Lee.Dr. Lee obtained his M.D. and Ph.D. degrees from the University of Pennsylvania in 2005 where he studied amyloid pathology in various experimental models under the mentorship of Virginia M.-Y. Lee, PhD.  After clinical training in Anatomic Pathology and Neuropathology at the Hospital of the University of Pennsylvania, he was appointed Assistant Professor in 2011 and promoted to Associate Professor with tenure in 2021 in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania.   In addition to being an attending pathologist,  Dr.Lee has   served in may leadership and research roles  , has  served on multiple study sections for the NIH and the DoD and is on the editorial board for various Neuropathology publications.Twitter: @TNRLabWebsite:  Home | Translational Neuropathology Research Laboratory | Perelman School of Medicine at the University of Pennsylvania (upenn.edu)

Hi friends! Welcome to episode 0 of my new podcast "Diversify in Path", a podcast that explores how  investing in diversity  can lead to  a high return of investment in pathology and lab medicine by learning from the knowledge and experiences of  diverse voices within in our field. For those who don't know me, I am currently a board certified Anatomic and clinical pathologist pursing fellowship training in Neuropathology and forensics. I switched into pathology from general surgery and have not ONCE regretted the change ….but noticed  an all to familiar pattern that I seen in med school, during residency interviews  and even during national pathology conferences .I want to say this is a project of the heart. A new endeavor  with the aims of this podcast to try to tell the stories of    those who add to the amazing diversity of pathology , laboratory medicine and the medical field as a whole. So join me as I interview collagues at various stages of their careers and in different areas of lab medicine  and hear how they think we can diversify in path Follow me on twitter: @bluehatcomics85 

In this episode we give a basic overview of common neurological disorders. We help you understand some of the common medical jargon and classification of brain diseases. You will learn more about traumatic brain injuries, epilepsy, dementia and more! Our hope is to keep the general public informed about topics and concerns within mental health and brain science. References: John Hopkins Medicine https://www.hopkinsmedicine.org/health/conditions-and-diseases/neurological-disorders Alzheimer's Organization https://www.alz.org/ Muhammad Ali Parkinson's Disease Inteview https://www.youtube.com/watch?v=-3l6diJ2oZ4 Parks, A. Clinical Neuropsychology 276: Neuropathology. Kansas City University. Class lecture.

These are exciting times at ODA - Dr. Richard French has been named Laboratory Director of the Ohio Animal Disease Diagnostic Laboratory! Dr. French is a Doctor of Veterinary Medicine with a Ph.D. and Residency in Neuropathology, and an MS in Parasitology, all from the University of Illinois. He completed a BS in Pathology at the University of Connecticut. Today, we chat with Dr. French and one of the ADDL microbiologists about what the lab currently does and where we see it heading in the future. Animal Disease Diagnostic Laboratory

Below is information that is apart of my analysis: The system set up to look into v reactions. This include a COVID v tab: https://www.openvaers.com/openvaers This is the study done in Dr. Paul Thomas's office of office visits for vaccinated kids versus unvaccinated: https://www.mdpi.com/1660-4601/17/22/8674?fbclid=IwAR0wH1PQK9GsonV2IIMY468D-dXCLv7bxLbkCc3jWRQUOS4uMfN4VI2LBHM You can also read his book: The Vaccine Friendly Plan Some articles that started to open my eyes about the aluminum in the v's: https://www.westonaprice.org/health-topics/vaccinations/aluminum-in-vaccines-what-everyone-needs-to-know/ https://www.sciencedirect.com/science/article/pii/S0946672X17300950 This is a link with a lot of education on immunity and vaccinations. It includes a link to their podcast: 'The Vaccine Conversation'. Episode 75&76 go in depth on aluminum in vaccine: https://immunityeducationgroup.org/podcast Additional Studies and Resources Referenced in Episode 75&76 (There is more if you follow the link above): https://www.jpands.org/vol21no4/miller.pdf Effects of aluminum on the neurotoxicity of primary cultured neurons and on the aggregations of beta-amyloid protein, Kawahara M, et al, Brain Research Bulletin 2001, May 15; 55(2):211-17. Effects of aluminum on the neurotoxicity of primary cultured neurons and on the aggregations of beta-amyloid protein, Kawahara M, et al, Brain Research Bulletin 2001, May 15; 55(2):211-17. Aluminum-adjuvanted vaccines transiently increase aluminum levels in murine brain tissue, Redhead K, et al, Pharmacology and Toxicology 1992, April; 70(4):278-80. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration, Shaw CA, Petrik MS, Journal of Inorganic Biochemistry, 2009 Nov; 103(11):1555-62. Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction, Couette M, et al, Journal of Inorganic Biochemistry, 2009, Nov; 103(11):1571-8. Aluminum impairs the glutamate-nitric oxide-cGMP pathway in cultured neurons and in rat brain in vivo: molecular mechanisms and implications for neuropathology, Canales JJ, et al, Journal of Inorganic Biochemistry 2001; 87(1-2):63-69. Neuropathology of aluminum toxicity in rats (glutamate and GABA impairment), El-Rhaman SS, Pharmacological Research 2003; 47(3):189-94. Systematic review of potential health risks posed by pharmaceutical, occupational, and consumer exposures to aluminum, aluminum oxides, aluminum hydroxide, and its soluble salts, Willhite CC, et al, Critical Reviews in Toxicology, 2014 Oct; 44 Suppl 4:1-80. Aluminum in brain tissue in autism, Mold M, et al, Journal of Trace Elements in Medicine and Biology 2018, Mar; 46:76-82. Aluminum in brain tissue in familial Alzheimer's disease, Mirza A, et al, Journal of Trace Elements in Medicine and Biology 2017, Mar; 40:30-36. Additional Resources: https://www.nvic.org/ The Vaccine Book by Robert W. Sears, MD, FAAP --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/anna-brayton/support

Paul and Max are joined by former Coventry and West Brom forward Garry Thompson, Neuropathology expert Dr Willie Stewart, former Everton midfielder Graham Stuart and Notts County skipper Tommy Doyle. See acast.com/privacy for privacy and opt-out information.

Dr. Vanessa Smith is a practicing neuropathologist. She received her MD from the Mayo Clinic. Following completion of her internship at the Mayo Clinic, she returned to her hometown of Lexington and completed an Anatomic Pathology residency, followed by a Neuropathology fellowship at the University of Kentucky. Academically, she has presented her research at several national and international meetings and has been published in multiple peer-reviewed journals. She also directed and taught several didactic curricula for pathology, neurosurgery and neurology residents, receiving a departmental teaching award for her efforts in resident education.   Take the quiz here

In this episode Dr. Graff and Dr. Conner interview Dr. Dugger about her journey to neuropathology and machine learning based research models for neurodegenerative disorders. Originally recorded in 2019.

In this episode of the podcast, Stephen Laureys interviews Sam Harris about meditation practice and the scientific study of the mind. They discuss why Sam began to practice meditation, the difference between dualistic and nondualistic mindfulness, the search for happiness, wisdom vs knowledge, our relationship with death, the Buddhist doctrine of rebirth, the hard problem of consciousness, the role of introspection in science, meditation and free will, the self and the brain, the difference between voluntary and involuntary actions, dangerous knowledge, the mystery of being, the power of hypnosis, and other topics. Steven Laureys, MD, PhD, FEAN (Fellow of the European Academy of Neurology), is a Belgian neurologist, neuroscientist, author, and speaker. He has written several publications including The Neurology of Consciousness: Cognitive Neuroscience and Neuropathology and the well-received La Méditation, c’est bon pour le cerveau, which will be published in English as The No-Nonsense Meditation Book in April 2021 (UK) and June 2021 (US). Dr. Laureys also maintains a clinical practice at the University Hospital of Liège where his research focuses on understanding consciousness, meditation, and the mind. Website: drstevenlaureys.org Twitter: @drstevenlaureys Email address mentioned in the podcast for the purpose of sharing information about an NDE (Near Death Experience): NDE@uliege.be

Aditya is a Neuropathologist at University Hospitals Plymouth, UK. He did his formal postgraduate training in Bombay obtaining MD (Path), DPB and DNB in Pathology and FRCPath (Neuropathology) from London He worked briefly as a Senior Registrar in NIMHANS followed by Higher Specialist Training in Neuropathology in Leeds and a short fellowship at the Massachusetts General Hospital, Boston. He has co-authored a book titled “Neuropathology Simplified” which serves as a beginners guide to Neuropathology. Aditya lives in Plymouth, UK with his wife, Veena and two children. He enjoyes, Hiking, Biking, Birding and art. You can read his professional profile here: https://www.plymouthhospitals.nhs.uk/shivane-a --- Send in a voice message: https://podcasters.spotify.com/pod/show/epistle91/message